Lv2
108 积分 2025-01-01 加入
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
12天前
已完结
Viral hepatitis and immunotherapy outcome in advanced hepatocellular carcinoma: A comprehensive umbrella review of 15 meta-analyses
20天前
已关闭
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
1个月前
已完结
Clinical Characteristics and Prognosis of Hepatocellular Carcinoma
1个月前
已完结
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
1个月前
已完结
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
1个月前
已完结
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
1个月前
已完结
Population-based differences in treatment outcome following anticancer drug therapies
1个月前
已完结
Subgroup Analysis by Prior Anti-VEGF or Anti-EGFR Target Therapy in FRESCO, a Randomized, Double-Blind, Phase III trial
1个月前
已完结
皖公网安备34019202002308
